GlassScriptPhysician profile
Sarah Lafferty
NPI 1336745470
$3,433.32
in general payments reported to CMS, 2019-2025
45 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $410 · 2022: $73.24 · 2023: $944 · 2024: $986 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,632 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,632.41 |
| Education | $317.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $359.04 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $242.76 | 2021-2025 | Imfinzi, Tagrisso, Enhertu |
| Exelixis INC. | $224.00 | 2023 | Cabometyx |
| Daiichi Sankyo INC. | $216.98 | 2022-2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $214.38 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Pfizer INC. | $200.32 | 2023-2024 | |
| Stemline Therapeutics INC. | $173.48 | 2023-2025 | Orserdu |
| Astellas Pharma US INC | $165.35 | 2023-2024 | Xospata, Vyloy |
| Incyte Corporation | $93.55 | 2021-2025 | Zynyz, Monjuvi, Pemazyre |
| Servier Pharmaceuticals LLC | $87.63 | 2023-2025 | |
| Janssen Biotech, INC. | $84.70 | 2022-2025 | Tecvayli, Rybrevant, Darzalex |
| Sanofi-Aventis U.S. LLC | $79.64 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.67 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $74.28 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $72.56 | 2023-2025 | Polivy, Alecensa, Tecentriq |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Lafferty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.